Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma Meeting Abstract
| Authors: | Patel, K.; Maris, M. B.; Cheson, B. D.; Zonder, J. A.; Lesokhin, A. M.; Von Keudell, G.; Seymour, E. K.; Lin, G. H. Y.; Catalano, T.; Shou, Y.; Iyer, S. P.; Ramchandren, R. |
| Abstract Title: | Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual Conference |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Language: | English |
| ACCESSION: | WOS:000560368301292 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.3030 |
| Notes: | Meeting Abstract: 3030 -- Source: Wos |
